Connectus Wealth’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-4,237
Closed -$421K 463
2023
Q4
$421K Buy
4,237
+2,016
+91% +$170K 0.01% 423
2023
Q3
$229K Sell
2,221
-47
-2% -$5.24K 0.01% 457
2023
Q2
$276K Sell
2,268
-167
-7% -$22.3K 0.01% 404
2023
Q1
$374K Buy
2,435
+240
+11% +$39.6K 0.01% 367
2022
Q4
$394K Buy
+2,195
New +$359K 0.01% 360

Other funds holding MRNA

Connectus Wealth's MRNA Position: Q1 2024 in Review

Connectus Wealth sold out of Moderna (MRNA) in Q1 2024, closing a stake of 4,237 shares — an estimated $421K sold.

Connectus Wealth first reported a position in MRNA in Q4 2022 and held it in 5 quarters. The position peaked at $421K in Q4 2023. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Connectus Wealth reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • Connectus Wealth sold 4,237 Moderna shares in Q1 2024, an estimated $421K.
  • Connectus Wealth first reported a position in Moderna in Q4 2022 and held it in 5 quarters.
  • Connectus Wealth's Moderna position peaked at $421K in Q4 2023.
  • 902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Connectus Wealth's 13F filing for Q1 2024, filed 14 May 2024.